JPH05228208A - Cellulose acetate base blood purifying hollow thread membrane and its manufacture - Google Patents

Cellulose acetate base blood purifying hollow thread membrane and its manufacture

Info

Publication number
JPH05228208A
JPH05228208A JP7515292A JP7515292A JPH05228208A JP H05228208 A JPH05228208 A JP H05228208A JP 7515292 A JP7515292 A JP 7515292A JP 7515292 A JP7515292 A JP 7515292A JP H05228208 A JPH05228208 A JP H05228208A
Authority
JP
Japan
Prior art keywords
cellulose
cellulose acetate
cda
cta
hollow fiber
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7515292A
Other languages
Japanese (ja)
Inventor
Kazutake Okamoto
和▲丈▼ 岡本
Hideo Sato
英雄 佐東
Mitsuru Suzuki
充 鈴木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyobo Co Ltd
Original Assignee
Toyobo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyobo Co Ltd filed Critical Toyobo Co Ltd
Priority to JP7515292A priority Critical patent/JPH05228208A/en
Publication of JPH05228208A publication Critical patent/JPH05228208A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE:To provide a blood purifying hollow thread membrane made of a cellulose acetate base material capable of being sterilized with high-pressure steam by setting the urea permeability coefficient of the hollow thread membrane made of a blended polymer of cellulose triacetate and cellulose diacetate at the specific ratio to a specific value. CONSTITUTION:In a cellulose acetate hollow thread membrane mainly made of cellulose triacetate (CTA) acetylated in a ratio acetylation of 60-62% and cellulose diacetate (CDA) acetylated in a ratio of 52-57%, the weight composition ratio of CTA to CDA is set to 95.0/5.0 to 55.0/45.0, and the permeability coefficient of urea is set to 30X10<-5>cm/sec or above. To manufacture it, the CTA and the CDA are mixed at the mixing ratio of 95.0/5.0 to 55.0/45.0 manufacture a dope, and it is extruded in a coagulation bath directly or indirectly through a double-ring nozzle. The CTA and the CDA are blended, and the objective hollow thread membrane having autoclave resistance and little change of solute permeability when processed with high-pressure steam can be obtained.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明はセルロ−ストリアセテ−
ト(CTA)とセルロ−スジアセテ−ト(CDA)をブ
レンドすることによる、高圧蒸気滅菌可能なセルロ−ス
アセテ−ト素材の血液浄化用中空糸膜及びその製造方法
に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention
TECHNICAL FIELD The present invention relates to a hollow fiber membrane for blood purification of a cellulose acetate material that can be sterilized under high pressure by blending cellulose (CTA) and cellulose diacetate (CDA), and a method for producing the same.

【0002】[0002]

【従来の技術】人工腎臓に用いられる膜は滅菌状態で使
用する必要がある。従来からの滅菌法としてはホルマリ
ン水充填滅菌、高圧蒸気滅菌(オートクレーブ滅菌)エ
チレンオキサイドガス滅菌、γ線滅菌等が知られてい
る。ホルマリン水充填滅菌、エチレンオキサイドガス滅
菌を行った膜については反復使用により膜に残留した微
量のホルマリン及びエチレンオキサイドが体内に蓄積さ
れるという問題が指摘されている。γ線滅菌については
その様な残留物の問題はないが、放射線の取扱、設備の
問題及び膜素材等の着色、劣化という問題が生じて来
る。これらの滅菌に対して、熱による滅菌、特に湿熱滅
菌が考えられる。第9改正日本薬局法には高気圧蒸気滅
菌法として115℃、30分間、121℃、20分間、
126℃、15分間の飽和蒸気圧中で加熱することによ
り微生物を滅菌する方法が規定されている。この熱によ
る滅菌法は、設備、取扱が容易であり残留毒性もなく使
用前の処理も容易であるという利点を有する。しかしな
がら現在熱滅菌型の人工腎臓として用いられてる膜はポ
リスルホン、再生セルロ−スくらいに過ぎない。セルロ
−ストリアセテ−ト、セルロ−スジアセテ−トは膜素材
として補体活性が低く溶質透過性に優れているがそれぞ
れ単一で高圧蒸気下でので熱処理を行うと結晶化、配向
化という現象が起こり十分な性能を得ることができな
い。
2. Description of the Related Art Membranes used for artificial kidneys must be used in a sterile condition. Known conventional sterilization methods include formalin water filling sterilization, high-pressure steam sterilization (autoclave sterilization), ethylene oxide gas sterilization, and γ-ray sterilization. It has been pointed out that a membrane that has been sterilized by filling with formalin water and sterilized with ethylene oxide gas has a problem that a small amount of formalin and ethylene oxide remaining in the membrane are accumulated in the body by repeated use. There is no such residue problem with γ-ray sterilization, but problems such as radiation handling, equipment problems, and coloring and deterioration of membrane materials and the like will occur. For these sterilizations, heat sterilization, particularly moist heat sterilization, can be considered. According to the 9th revised Japanese Pharmacy Law, as high pressure steam sterilization method, 115 ℃, 30 minutes, 121 ℃, 20 minutes,
A method for sterilizing microorganisms by heating in a saturated vapor pressure at 126 ° C. for 15 minutes is specified. This heat sterilization method has the advantages that it is easy to install and handle, has no residual toxicity, and can be easily treated before use. However, the membranes currently used as heat sterilization type artificial kidneys are only polysulfone and regenerated cellulose. Cellulose triacetate and cellulose diacetate have low complement activity and excellent solute permeability as membrane materials, but when they are individually treated under high pressure steam, heat treatment causes crystallization and orientation phenomena. It is not possible to obtain sufficient performance.

【0003】[0003]

【発明が解決しようとする課題】本発明はセルロ−スト
リアセテ−ト、セルロ−スジアセテ−トを適切な比でブ
レンドすることによりオートクレーブ滅菌しても優れた
溶質透過性(耐オ−トクレ−ブ性)を有するセルロ−ス
アセテ−ト系中空糸膜、及びその製造法を提供すること
である。
DISCLOSURE OF THE INVENTION The present invention provides excellent solute permeability (autoclave resistance) even by autoclave sterilization by blending cellulose-stearate and cellulose diacetate in an appropriate ratio. The present invention provides a cellulose acetate hollow fiber membrane having a) and a method for producing the same.

【0004】[0004]

【課題を解決するための手段】本発明は (1) 酢化度60〜62%のセルロ−ストリアセテ−ト
(CTA)と酢化度52〜57%のセルロ−スジアセテ
−ト(CDA)を主成分とするセルロ−スアセテ−ト系
中空糸膜であって、前記CTAとCDAの重量組成比が
95.0/5.0〜55.0/45.0 であり、かつ尿素の透過係数が8
0×10-5cm/sec以上であるセルロースアセテート系血
液浄化用中空糸膜及び121℃、20分高圧蒸気処理後
の尿素の透過係数が55×10-5cm/sec以上であるセル
ロースアセテート系血液浄化用中空糸膜 (2)前記セルロ−ストリアセテ−ト(CTA)と前記
セルロ−スジアセテ−ト(CDA)の混合比が95.0/5.0
〜55.0/45.0 であるド−プを作製し、二重環ノズルを通
して直接的又は間接的に凝固浴中に押し出すことを特徴
とするセルロースアセテート系血液浄化用中空糸膜の製
造方法である。
Means for Solving the Problems The present invention mainly comprises (1) mainly cellulose acetate (CTA) having an acetylation degree of 60 to 62% and cellulose diacetate (CDA) having an acetylation degree of 52 to 57%. A cellulose acetate-based hollow fiber membrane as a component, wherein the weight composition ratio of CTA and CDA is
95.0 / 5.0 to 55.0 / 45.0, and a urea permeability coefficient of 8
Cellulose acetate-based hollow fiber membrane for blood purification with 0 × 10 -5 cm / sec or more and cellulose acetate-based with urea permeability coefficient of 55 × 10 -5 cm / sec or more after high-pressure steam treatment at 121 ° C. for 20 minutes Hollow fiber membrane for blood purification (2) The mixing ratio of the cellulose triacetate (CTA) and the cellulose diacetate (CDA) is 95.0 / 5.0.
A method for producing a cellulose acetate-based hollow fiber membrane for blood purification, characterized in that a dope of ~ 55.0 / 45.0 is produced and extruded directly or indirectly into a coagulation bath through a double ring nozzle.

【0005】本発明でいうセルロ−ストリアセテ−ト
(CTA)とは酢化度60−62%、セルロ−スジアセ
テ−ト(CDA)とは酢化度52−57%のセルロ−ス
アセテ−トであって、その酢化度は次の式で求める。 酢化度(%)=(アセチル基酢酸換算の質量/セルロ−
スアセテ−ト全体の質量)×100
In the present invention, cellulose acetate (CTA) means acetylation degree of 60-62%, and cellulose diacetate (CDA) means cellulose acetate having acetylation degree of 52-57%. The degree of acetylation is calculated by the following formula. Acetylation degree (%) = (mass in terms of acetyl group acetic acid / cellulosic)
Total mass of suacetate) x 100

【0006】本発明における中空糸膜は前記セルロ−ス
トリアセテ−トと前記セルロ−スジアセテ−トとを10
重量%以上の濃度になるよう非溶媒を添加した沸点15
0℃以上の非プロトン性極性溶媒に溶解しド−プとした
ものを二重環ノズルに通して上記溶媒と非溶媒の水溶液
からなる凝固浴中に押し出され製膜される。溶媒/非溶
媒の混合比は50/50〜90/10である。ここで、
吐出温度(T1)と凝固浴温度(T2)が0<T1−T
2<100(℃)となるように制御することが高い透過
性能を得るために重要である。
The hollow fiber membrane according to the present invention comprises 10 parts of the cellulose acetate and the cellulose diacetate.
Boiling point 15 with non-solvent added to achieve a concentration of over 15% by weight
A dope, which is dissolved in an aprotic polar solvent at 0 ° C. or higher, is passed through a double ring nozzle and extruded into a coagulation bath composed of an aqueous solution of the above solvent and a non-solvent to form a film. The solvent / non-solvent mixing ratio is 50/50 to 90/10. here,
Discharge temperature (T1) and coagulation bath temperature (T2) are 0 <T1-T
It is important to control so that 2 <100 (° C.) in order to obtain high transmission performance.

【0007】ノズルから凝固浴へのポリマードープの押
出しは、凝固浴中に直接押し出す直接法、ノズルと凝固
浴表面の間にエアーギャップを設けて、ノズルから一旦
空気中に押出し凝固浴へ導く間接法いずれの方法でも応
用可能である。またポリマードープをノズルから吐出す
る際中空内部に流動パラフィンの如き液体を共存させ紡
糸することも可能であるが、本発明では中空内部に不活
性ガスを適正流量流しながら紡糸する方法が望ましい。
The extrusion of the polymer dope from the nozzle into the coagulation bath is a direct method of direct extrusion into the coagulation bath, or an indirect method of extruding the polymer dope into the air through the nozzle by providing an air gap between the nozzle and the surface of the coagulation bath. Any method can be applied. Further, when the polymer dope is discharged from the nozzle, it is possible to spin a liquid such as liquid paraffin inside the hollow, but in the present invention, a method of spinning while flowing an inert gas at an appropriate flow rate in the hollow is preferable.

【0008】非プロトン性極性溶媒としては、N−メチ
ルピロリドン、ジメチルホルムアミド、ジメチルアセト
アミド、ジメチルスルホキシド等が、非溶媒としては、
エチレングリコ−ル、トリエチレングリコ−ル、ポリエ
チレングリコ−ル、グリセリン、ポリプロピレングリコ
−ル等の多価アルコ−ルやメタノ−ル、エタノ−ル等の
アルコ−ル類等が使用できる。更にこの中空糸膜は、凝
固浴、水洗浴を経て親水化浴にて親水化される。親水化
剤としてグリセリン、ポリエチレングリコ−ル等の多価
アルコ−ルの他メタノ−ル、エタノ−ル等のアルコ−ル
−類が使用できる。その後、中空糸膜は乾燥工程を経て
巻取られる。
As the aprotic polar solvent, N-methylpyrrolidone, dimethylformamide, dimethylacetamide, dimethylsulfoxide and the like are used, and as the nonsolvent,
Polyhydric alcohols such as ethylene glycol, triethylene glycol, polyethylene glycol, glycerin and polypropylene glycol, and alcohols such as methanol and ethanol can be used. Further, this hollow fiber membrane is hydrophilized in a hydrophilization bath through a coagulation bath and a water washing bath. As the hydrophilizing agent, polyhydric alcohols such as glycerin and polyethylene glycol, and alcohols such as methanol and ethanol can be used. Then, the hollow fiber membrane is wound through a drying process.

【0009】セルロ−ストリアセテ−ト中空糸に高圧蒸
気下で熱処理を行うと結晶化が進行し糸長方向及び半径
方向に収縮し、著しく性能が低下してしまう。また、セ
ルロ−スジアセテ−ト中空糸においては配向化により糸
長方向に伸長し中空糸膜としての形状保持が困難とな
る。したがってセルロ−ストリアセテ−トにセルロ−ス
ジアセテ−トを添加することによりセルロ−ストリアセ
テ−トの結晶化を抑制し、さらには収縮も抑制すること
ができオ−トクレ−ブ処理後、初期の性能を保つことが
出来ると考えられる。セルロ−ストリアセテ−ト(CT
A)とセルロ−スジアセテ−ト(CDA)の混合割合は
95.0/5.0〜55.0/45.0 が適性であり、好ましくは90/10
〜70/30 である。
When heat treatment is performed on the cellulose triacetate hollow fiber under high pressure steam, crystallization progresses and shrinks in the yarn length direction and in the radial direction, resulting in a marked decrease in performance. Further, in the cellulose diacetate hollow fiber, it is difficult to maintain the shape of the hollow fiber membrane because the cellulose fiber is stretched in the fiber length direction due to orientation. Therefore, by adding cellulose diacetate to the cellulose acetate, it is possible to suppress the crystallization of the cellulose acetate and further suppress the shrinkage, and after the autoclave treatment, the initial performance is improved. It is thought that it can be maintained. Cellulostriate (CT
The mixing ratio of A) and cellulose diacetate (CDA) is
95.0 / 5.0 to 55.0 / 45.0 is suitable, preferably 90/10
It is ~ 70/30.

【0010】溶質の透過係数Pは次式のように定義され
る。 P=Qb/A×ln(C1/C2) ここで、Qb:血液流速(ミリリットル/分) A :膜面積(cm2 ) C1:入り口溶質濃度 C2:出口溶質濃度
The solute permeation coefficient P is defined by the following equation. P = Qb / A × ln (C1 / C2) where Qb: blood flow rate (milliliter / min) A: membrane area (cm 2 ) C1: inlet solute concentration C2: outlet solute concentration

【0011】本発明のセルロースアセテート系中空糸膜
の透水性(UFR)は3〜250ml/m2/hr/mmHgであ
る。またここで言う尿素の透過性とは121℃、20
分、高圧蒸気処理前の尿素の透過係数を意味しその値が
80×10-5cm/sec以上であるが、 95.0/5.0 未満ではセル
ロ−スジアセテ−ト添加の効果が得られずオ−トクレ−
ブ後の初期性能の保持性が非常に低くなり、一方55.0/4
5.0 を超えると性能保持性は高いが初期性能自体が低く
なる。以上の理由によりセルロ−ストリアセテ−トとセ
ルロ−スジアセテ−トの混合割合は95.0/5.0から55.0/4
5.0 が適している。
The water permeability (UFR) of the cellulose acetate hollow fiber membrane of the present invention is 3 to 250 ml / m 2 / hr / mmHg. In addition, the permeability of urea here is 121 ° C., 20
Min, the permeation coefficient of urea before high-pressure steam treatment, and its value is
80 × 10 -5 cm / sec or more, but if it is less than 95.0 / 5.0, the effect of adding cellulose diacetate cannot be obtained and auto-cure
The initial performance after squeezing is very low, while 55.0 / 4
When it exceeds 5.0, the performance retention is high, but the initial performance itself is low. For the above reasons, the mixing ratio of cellulose triacetate and cellulose diacetate was from 95.0 / 5.0 to 55.0 / 4.
5.0 is suitable.

【0012】また、本発明の血液浄化用中空糸膜からな
る透析器は人工肺、人工肝臓、人工膵臓等にも十分応用
できるものである。以下実施例、比較例により本発明の
詳細を説明する。
Further, the dialyzer comprising the hollow fiber membrane for blood purification of the present invention can be sufficiently applied to artificial lung, artificial liver, artificial pancreas and the like. Hereinafter, the present invention will be described in detail with reference to Examples and Comparative Examples.

【0013】[0013]

【実施例】【Example】

(実施例1)酢化度60.8%のセルロ−ストリアセテ
−ト/酢化度55.0%のセルロ−スジアセテ−トを重
量比8/2、ポリマ−濃度20%、N−メチルピロリド
ン64%、トリエチレングリコ−ル16%を混合しド−
プとした。これを二重環ノズルを用いてN−メチルピロ
リドン24%、トリエチレングリコ−ル6%水溶液から
なる凝固液に吐出し、水洗浴、グリセリン親水化浴、乾
燥工程を経て中空糸膜を得た。吐出温度、凝固浴温度は
それぞれ130℃、50℃であった。グリセリン浴は5
0℃、50%水溶液であった。得られた中空糸膜は外径
約200μm、膜厚約15μmの真円を成していた。こ
の中空糸繊維を800本、25cmの長さに束ね(膜面
積0.0754m2)アクリルパイプにウレタン接着して
テスト用ミニモジュ−ルを作製した。このミニモジュ−
ルに121℃20分のオ−トクレ−ブ処理を行い処理前
後の性能の変化を表1に示す。尚、尿素の透過性は前記
ミニモジュールを用いて血液側に尿素5g/l液を17
ミリリットル/分(Qb)、透析側に透析液(純水)4
00ミリリットルを2リットル/分で流した。透析液は
常に撹拌し400ミリリットルの容量を保ち、2リット
ル/分で部分的に、純水と入れかわるようにした。測定
温度は37℃である。結果を表1(単位:×10-5cm/s
ec)に示す。表1によると尿素透過性の初期性能及びオ
−トクレ−ブ後の性能も高く十分実用に供し得る。
(Example 1) Cellulose triacetate having an acetylation degree of 60.8% / cellulose diacetate having an acetylation degree of 55.0% were in a weight ratio of 8/2, a polymer concentration was 20% and N-methylpyrrolidone 64 %, Triethylene glycol 16% were mixed and
I thought This was discharged into a coagulation liquid consisting of an aqueous solution of 24% N-methylpyrrolidone and 6% triethylene glycol using a double ring nozzle, and a hollow fiber membrane was obtained through a washing bath, a glycerin hydrophilization bath and a drying step. .. The discharge temperature and the coagulation bath temperature were 130 ° C. and 50 ° C., respectively. 5 for glycerin bath
It was a 50% aqueous solution at 0 ° C. The obtained hollow fiber membrane was a perfect circle having an outer diameter of about 200 μm and a film thickness of about 15 μm. 800 hollow fibers were bundled in a length of 25 cm (membrane area: 0.0754 m 2 ) and bonded to an acrylic pipe with urethane to prepare a mini-module for testing. This mini module
Table 1 shows the change in performance before and after the autoclave treatment at 121 ° C. for 20 minutes. In addition, the permeability of urea was measured by using the above-mentioned mini-module and the amount of urea 5 g / l solution was 17
Milliliter / min (Qb), dialysate (pure water) 4 on the dialysis side
00 ml was run at 2 l / min. The dialysate was constantly stirred to maintain a volume of 400 ml and partially replaced with pure water at 2 l / min. The measurement temperature is 37 ° C. The results are shown in Table 1 (unit: × 10 -5 cm / s
ec). According to Table 1, the initial performance of urea permeability and the performance after autoclave are high and can be sufficiently put to practical use.

【0014】[0014]

【表1】 [Table 1]

【0015】(実施例2)実施例1と同じセルロ−スト
リアセテ−ト/セルロ−スジアセテ−トを重量比9/1
として実施例1と同様の条件で中空糸膜を製造、オ−ト
クレ−ブ処理を行った。結果を表1に示す。その結果、
実施例1と同様に尿素透過性の初期性能及びオ−トクレ
−ブ後の性能も高く十分実用に供し得る。
(Example 2) The same cellulose triacetate / cellulose diacetate as in Example 1 was used in a weight ratio of 9/1.
A hollow fiber membrane was manufactured under the same conditions as in Example 1 and subjected to autoclave treatment. The results are shown in Table 1. as a result,
Similar to Example 1, the initial performance of urea permeability and the performance after autoclave are high and can be sufficiently put to practical use.

【0016】(実施例3)実施例1と同じセルロ−スト
リアセテ−ト/セルロ−スジアセテ−トを重量比7/3
として実施例1と同様の条件で中空糸膜を製造、オ−ト
クレ−ブ処理を行った。結果を表1に示す。その結果、
若干尿素透過初期性能が低下するもののオ−トクレ−ブ
後の性能保持性は高く十分実用に供し得る。
(Example 3) The same cellulose triacetate / cellulose diacetate as in Example 1 was used in a weight ratio of 7/3.
A hollow fiber membrane was manufactured under the same conditions as in Example 1 and subjected to autoclave treatment. The results are shown in Table 1. as a result,
Although the urea permeation initial performance is slightly lowered, the performance retention after autoclave is high and it can be sufficiently put to practical use.

【0017】(比較例1)実施例1と同じセルロ−スト
リアセテ−ト/セルロ−スジアセテ−トを重量比で4/
6として実施例1と同様の条件で中空糸膜を製造、オ−
トクレ−ブ処理を行った。結果を表1に示す。その結
果、尿素透過初期性能自体が低いため実用的ではない。
(Comparative Example 1) The same cellulose striatate / cellulose diacetate as in Example 1 was used in a weight ratio of 4 /.
6, a hollow fiber membrane was produced under the same conditions as in Example 1, and
A toclave treatment was performed. The results are shown in Table 1. As a result, the urea permeation initial performance itself is low, which is not practical.

【0018】(比較例2)実施例1と同じセルロ−スト
リアセテ−ト単一でポリマ−濃度20%として実施例1
と同様の条件で中空糸膜を製造、オ−トクレ−ブ処理を
行った。結果を表1に示す。その結果、尿素透過初期性
能は高いがオ−トクレ−ブ後の性能保持率は低いため実
用的でない。
(Comparative Example 2) The same cellulosic triacetate as in Example 1 was used alone, and the polymer concentration was 20%.
A hollow fiber membrane was produced under the same conditions as above and subjected to autoclave treatment. The results are shown in Table 1. As a result, the initial urea permeation performance is high, but the performance retention rate after autoclave is low, which is not practical.

【0019】[0019]

【発明の効果】本発明によるとき、セルロ−ストリアセ
テ−ト、セルロ−スジアセテ−トをブレンドすることに
より高圧蒸気処理を行っても溶質透過性の変化の少ない
耐オ−トクレ−ブ性を有する中空糸膜を提供することが
できる。
Industrial Applicability According to the present invention, a hollow having autoclave resistance with little change in solute permeability even when subjected to high pressure steam treatment by blending cellulose striatate and cellulose diacetate. A thread film can be provided.

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 酢化度60〜62%のセルローストリア
セテート(以下CTAと記す)と酢化度52〜57%の
セルロ−スジアセテ−ト(以下CDAと記す)を主成分
とするセルロースアセテート系中空糸膜であって前記C
TAとCDAの重量組成比が95.0/5.0〜55.0/45.0 であ
り、尿素の透過係数が80×10-5cm/sec以上であるセルロ
−スアセテ−ト系血液浄化用中空糸膜。
1. A cellulose acetate-based hollow containing, as main components, cellulose triacetate having an acetylation degree of 60 to 62% (hereinafter referred to as CTA) and cellulose diacetate (hereinafter referred to as CDA) having an acetylation degree of 52 to 57%. It is a thread film and is C
A cellulose acetate-based hollow fiber membrane for blood purification, in which the weight composition ratio of TA and CDA is 95.0 / 5.0 to 55.0 / 45.0, and the permeability coefficient of urea is 80 × 10 −5 cm / sec or more.
【請求項2】 請求項1に記載のCTAとCDAを主成
分とするセルロースアセテート系中空糸膜であって、該
CTAとCDAの重量組成比が95.0/5.0〜55.0/45.0 で
あり、121℃、20分高圧蒸気処理後の尿素の透過係
数が55×10-5cm/sec以上であるセルロースアセテート系
血液浄化用中空糸膜。
2. The cellulose acetate-based hollow fiber membrane containing CTA and CDA as main components according to claim 1, wherein the weight composition ratio of CTA and CDA is 95.0 / 5.0 to 55.0 / 45.0, and 121 ° C. A cellulose acetate-based blood purification hollow fiber membrane having a urea permeability coefficient of 55 × 10 −5 cm / sec or more after high-pressure steam treatment for 20 minutes.
【請求項3】 酢化度60〜62%のセルロ−ストリア
セテ−ト(CTA)と酢化度52〜57%のセルロ−ス
ジアセテ−ト(CDA)の混合比が95.0/5.0〜55.0/45.
0 であるド−プを作製し二重環ノズルを通して直接また
は間接的に凝固浴中に押し出すことを特徴とするセルロ
ースアセテート系血液浄化用中空糸膜の製造方法。
3. A mixing ratio of cellulose acetate (CTA) having an acetylation degree of 60 to 62% and cellulose diacetate (CDA) having an acetylation degree of 52 to 57% is 95.0 / 5.0 to 55.0 / 45.
A method for producing a cellulose acetate-based hollow fiber membrane for blood purification, which comprises producing a dope of 0 and extruding it directly or indirectly into a coagulation bath through a double ring nozzle.
JP7515292A 1992-02-25 1992-02-25 Cellulose acetate base blood purifying hollow thread membrane and its manufacture Pending JPH05228208A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP7515292A JPH05228208A (en) 1992-02-25 1992-02-25 Cellulose acetate base blood purifying hollow thread membrane and its manufacture

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7515292A JPH05228208A (en) 1992-02-25 1992-02-25 Cellulose acetate base blood purifying hollow thread membrane and its manufacture

Publications (1)

Publication Number Publication Date
JPH05228208A true JPH05228208A (en) 1993-09-07

Family

ID=13567950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7515292A Pending JPH05228208A (en) 1992-02-25 1992-02-25 Cellulose acetate base blood purifying hollow thread membrane and its manufacture

Country Status (1)

Country Link
JP (1) JPH05228208A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0636403A2 (en) * 1993-07-28 1995-02-01 Toyo Boseki Kabushiki Kaisha Cellulose acetate hemodialysis membrane
JPH08169801A (en) * 1994-12-19 1996-07-02 Nissho Corp Oxygenator for organ-storing apparatus
US6632366B1 (en) 1999-05-31 2003-10-14 Daicel Chemical Industries, Ltd. Cellulose compound hollow fiber membrane

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0636403A2 (en) * 1993-07-28 1995-02-01 Toyo Boseki Kabushiki Kaisha Cellulose acetate hemodialysis membrane
EP0636403A3 (en) * 1993-07-28 1996-03-27 Toyo Boseki Cellulose acetate hemodialysis membrane.
US5624561A (en) * 1993-07-28 1997-04-29 Toyo Boseki Kabushiki Kaisha Cellulose acetate hemodialysis membrane
US5783124A (en) * 1993-07-28 1998-07-21 Toyo Boseki Kabushiki Kaisha Cellulose acetate hemodialysis membrane
JPH08169801A (en) * 1994-12-19 1996-07-02 Nissho Corp Oxygenator for organ-storing apparatus
US6632366B1 (en) 1999-05-31 2003-10-14 Daicel Chemical Industries, Ltd. Cellulose compound hollow fiber membrane

Similar Documents

Publication Publication Date Title
US5938929A (en) Polysulfone hollow fiber semipermeable membrane
JP4848278B2 (en) Highly permeable hollow fiber membrane blood purifier and method for producing the same
US4035459A (en) Process for spinning dry-fiber cellulose acetate hollow fiber membranes
US4780205A (en) Permselective hollow fiber membrane, process for the preparation thereof, method and apparatus for plasma components separation
CA2202969C (en) Selectively permeable hollow fiber membrane and process for producing same
EP0066408A2 (en) Porous membrane
US20040206692A1 (en) Hollow fiber membrane for purifying blood
EP0012630B1 (en) Process for producing a cellulose acetate-type permselective membrane, permselective membrane thus produced, and use of such membrane in artificial kidney
EP0850678B1 (en) Process for producing hollow fiber membrane, hollow fiber membrane, and dialyzer of hollow fiber membrane type
US4886631A (en) Cellulose ester hollow fiber membrane for plasma separation
JP3427658B2 (en) Cellulose hollow fiber membrane and method for producing the same
JPH05228208A (en) Cellulose acetate base blood purifying hollow thread membrane and its manufacture
US5897817A (en) Process for making a medical device from a cellulose acetate hollow fiber semipermeable membrane
JP4352709B2 (en) Polysulfone-based semipermeable membrane and artificial kidney using the same
EP0824960A1 (en) Hollow-fiber membrane of polysulfone polymer and process for the production thereof
JPH0120245B2 (en)
JPH0970431A (en) Production of polysulfone hollow fiber type artificial kidney and artificial kidney
JPS61185305A (en) Preparation of cellulose acetate hollow yarn
JPH07289866A (en) Polysulfone-based selective permeable membrane
JP2011020071A (en) Method for manufacturing polysulfone-based hollow fiber membrane
JP2855233B2 (en) Method for producing aromatic polysulfone semipermeable membrane having excellent water permeability
JPH0751362A (en) Hemo-dialyzer
JPS6411322B2 (en)
JP2005021510A (en) Highly permeabile hollow fiber type hemocatharsis device
KR20050078748A (en) A blood compatible hollow fiber membrane, and a process of preparing for the same